Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Phaos Technology Holdings Cayman Cash Conversion Cycle Related Terms
Phaos Technology Holdings Cayman Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
POAS vs WOK, ITOC, INBS: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, Phaos Technology Holdings Cayman's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phaos Technology Holdings Cayman Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Phaos Technology Holdings Cayman's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Phaos Technology Holdings Cayman's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phaos Technology Holdings Cayman (POAS) has a Cash Conversion Cycle of 928.54 as of Oct. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Phaos Technology Holdings Cayman and its competitors.
Is Phaos Technology Holdings Cayman's Cash Conversion Cycle too high?
Phaos Technology Holdings Cayman's current Cash Conversion Cycle is 928.54. The Medical Devices & Instruments industry median Cash Conversion Cycle is 159.09. Phaos Technology Holdings Cayman's value of 928.54 is 483.7% above this industry median. Overall, Phaos Technology Holdings Cayman has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Phaos Technology Holdings Cayman's Cash Conversion Cycle compare to WOK and ITOC?
Phaos Technology Holdings Cayman's Cash Conversion Cycle of 928.54 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 159.09. Phaos Technology Holdings Cayman's value of 928.54 is 483.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 159.09, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Phaos Technology Holdings Cayman's current Cash Conversion Cycle of 928.54 is 483.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Phaos Technology Holdings Cayman and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 159.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Phaos Technology Holdings Cayman's current Cash Conversion Cycle is 928.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phaos Technology Holdings Cayman stock overvalued right now?
Phaos Technology Holdings Cayman (POAS) has a current Cash Conversion Cycle of 928.54. The current Cash Conversion Cycle is 928.54 and 483.7% above the Medical Devices & Instruments industry median of 159.09. Phaos Technology Holdings Cayman's overall GF Score™ is 4/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Phaos Technology Holdings Cayman (POAS), the current Cash Conversion Cycle is 928.54 as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Phaos Technology Holdings Cayman Business Description
Phaos Technology Holdings Cayman Ltd is an investment holding company incorporated in the Cayman Islands. Through its subsidiaries, the Company engages in the research, development, manufacturing, and commercialization of advanced optical technologies and products. Leveraging its patented microsphere technology, Phaos enhances the magnification of traditional optical microscopes, enabling visualization beyond the 200nm optical limit at a commercially viable working distance. The Company offers advanced microscopy equipment and parts, along with AI-powered software solutions that complement its hardware to deliver fully integrated microscopy systems. Its technologies serve diverse sectors, including manufacturing, biomedical, and research.
4GF Score
Get the complete analysis for POAS
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
POAS has been successfully added to your 
